Dejan Juric

40PUBLICATIONS
434CO-AUTHORS
Predictive and prognostic markersMolecular targetsPacific Peoples theory of change models for healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Oct 22, 2026
Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer.

|Jul 02, 2026
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Mar 20, 2026
Perceptions of Prognosis and Hope Among Patients With Advanced Cancer at the Time of Enrollment in an Early-Phase Clinical Trial.

Mary C Boulanger, Debra M Lundquist, Andrea Pelletier

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Oct 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Dejan Juric, Daniel Anderson, Afshin Dowlati

Pageof 7

Frequent Collaborators

11 joint publications

Aditya Bardia

8 joint publications

Steven J Isakoff

7 joint publications

Ryan B Corcoran

7 joint publications

Leif W Ellisen